A Part of Recovery That Oncologists Rarely Address

A Part of Recovery That Oncologists Rarely Address

For women who have been through cancer treatment — chemotherapy, radiation, surgical procedures, or hormonal therapies — sexual health changes are among the most significant and least addressed quality-of-life impacts. Studies consistently show that sexual dysfunction affects 40–100% of women after cancer treatment, depending on diagnosis and treatment type. Yet sexual health concerns are raised in fewer than 25% of follow-up oncology appointments. This is a gap worth closing. Sexual wellbeing is a dimension of quality of life that women have a right to address — during and after cancer treatment.

How Cancer Treatments Affect Female Sexual Health

Chemotherapy

Chemotherapy can trigger premature menopause in premenopausal women through ovarian damage. Even without premature menopause, it causes fatigue, nausea, nerve damage (neuropathy), and changes in body image that affect sexual interest and response.

Hormone-Suppressing Therapies

Treatments for hormone receptor-positive breast cancer — aromatase inhibitors (AIs) and tamoxifen — profoundly affect sexual health. Aromatase inhibitors create surgical-menopause-like estrogen deficiency, causing severe vaginal dryness, dyspareunia, and loss of clitoral sensitivity. Tamoxifen has mixed effects but frequently causes vaginal dryness.

Pelvic Radiation

Radiation to the pelvis (for gynecological, colorectal, or cervical cancers) causes vaginal fibrosis, stenosis, and severe changes to tissue health. Vaginal dilation therapy is often required to maintain tissue function.

Surgical Menopause

Bilateral oophorectomy (ovary removal) creates an immediate, complete cessation of estrogen and testosterone production. The sexual health effects are rapid and often more severe than gradual natural menopause.

Safe Treatment Options After Cancer

The question of hormone therapy after cancer is complex and highly diagnosis-specific. However, many non-systemic options are available:

• Topical vaginal estrogen — many oncologists now support low-dose local estrogen for women with breast cancer given its minimal systemic absorption, particularly for women on AIs
• Ospemifene and intravaginal DHEA — alternatives with different mechanisms and risk profiles
• Vaginal moisturizers and lubricants — always appropriate and should be started proactively
• Pelvic floor physical therapy — critical after pelvic radiation or pelvic surgery
• Prescription topical arousal support — for women with reduced sensitivity who have been cleared by their oncologist, local treatments like Climax RX can address sensitivity without systemic hormonal effects

Always involve your oncologist in sexual health treatment decisions. The landscape of what’s safe after different cancer diagnoses is evolving rapidly.

The Psychological Dimension

Cancer changes the relationship with one’s body in profound ways. Body image, fear of recurrence, grief about fertility, and the emotional weight of the cancer experience all affect sexual confidence and desire. Oncological social workers, sex therapists specializing in cancer, and support groups provide essential support alongside medical treatment.

FAQ

Is it safe to address sexual wellness during active cancer treatment?

It depends on the treatment type and stage. During active chemotherapy or radiation, the priority is tolerating treatment. But proactive discussion with your care team about protecting sexual health — including starting lubricants early — is appropriate during treatment.

Is vaginal estrogen safe after breast cancer?

This is nuanced. For most women on aromatase inhibitors with severe vaginal symptoms, low-dose topical vaginal estrogen is increasingly supported by oncologists given its minimal systemic absorption. For women with ER-positive breast cancer, the risk-benefit discussion with your oncologist is essential.

When can I start addressing sexual wellness after treatment ends?

There’s no mandatory waiting period for starting vaginal moisturizers or lubricants. For hormonal treatments and prescription topicals, clearance from your oncology team is appropriate regardless of timing.